TAAR1 and Cognitive impairment: TAAR1 agonists are proposed to potentially possess efficacy across a wider spectrum of symptom domains than the current antipsychotics acting as D2R antagonists, including negative symptoms and cognitive impairment, while exhibiting a reduced propensity for side-effects11.